logo

For the Inventor, By the Inventor

Parkville, Australia

Csl Limited


USPTO Granted Patents = 123

% Expired Patents = 17.9



Trademarks = 10

Forward Citations = 622

Loading Chart...
Loading Chart...

155 inventors (with patents filed for the assignee):

goldMedal Andrew Donald Nash (19 out of 29 patents)

silverMedal Con Panousis (16 out of 19 patents)

bronzeMedal Gary Lee Warren (11 out of 11 patents)

4.  Yvonne Vucica (11 out of 11 patents)

5.  Manuel Baca (11 out of 33 patents)

6.  Veronika Rayzman (9 out of 9 patents)

7.  Michael Wilson (7 out of 10 patents)

8.  Marc Nolte (7 out of 24 patents)

9.  William Strohl (7 out of 29 patents)

10.  Matthew Hardy (7 out of 9 patents)

11.  Kirsten Edwards (7 out of 7 patents)

12.  Hubert Metzner (7 out of 28 patents)

13.  Louis Jerry Fabri (7 out of 16 patents)

14.  Zhiqiang An (7 out of 43 patents)

15.  Ian George Barr (7 out of 8 patents)


Core Competencies:
Therapeutic Antibodies
Diabetic Nephropathy
Inflammatory Bowel Disease
Neurological Conditions
Apolipoprotein A-I
VEGF-B Signaling
High Density Lipoprotein
G-CSF Receptor
Factor VIII
Interleukin-13
Antibody Purification
Immune Response

123 patents:

1. 12630616 - Complement C2 Binding Proteins and Uses Thereof (2026-05-19),
2. 12281160 - Method of treating asthma (2025-04-21),
3. 12264202 - Methods of reducing or hindering development of ischemia-reperfusion injury due to kidney transplantation with an antibody that inhibits granulocyte-colony stimulating factor (G-CSF) signaling (2025-04-01),
4. 12071484 - Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein (2024-08-27),
5. 11957731 - Reconstituted HDL formulation (2024-04-16),
6. 11840573 - CD131 binding proteins and uses thereof (2023-12-12),
7. 11732028 - Contaminant removal method (2023-08-22),
8. 11723953 - Reconstituted high density lipoprotein formulation and production method thereof (2023-08-15),
9. 11510968 - Method for improving the stability of purified Factor VIII after reconstitution (2022-11-29),
10. 11505619 - Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease (2022-11-22),
11. 11466073 - Human serum albumin variants and uses thereof (2022-10-11),
12. 11464828 - Reconstituted HDL formulation (2022-10-11),
13. 11345759 - Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies (2022-05-31),
14. 11279750 - Process for preparing apolipoprotein A-I (Apo A-I) (2022-03-22),
15. 11261243 - Methods of treating diabetic nephropathy by administering an anti-vegf-b (vascular endothelial growth factor-b) antibody (2022-03-01),
Company Overview
CSL Limited is a global biotechnology company headquartered in Parkville, Australia, specializing in the development and manufacture of innovative therapeutic antibodies. The company focuses on addressing critical health challenges, particularly in areas such as diabetic nephropathy, inflammatory bowel disease, and neurological conditions. CSL's research encompasses advanced technologies related to apolipoprotein A-I, VEGF-B signaling, and G-CSF receptor, positioning it as a leader in the biopharmaceutical industry dedicated to improving patient outcomes worldwide.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Csl Limited USPTO Patent Assignee Logo
123 Patents

#1 in Parkville

#22 in Australia

#6,520 in the World

Parkville, AU
Parkville, Australia

Csl Limited

Forward Citations = 622

155 inventors:

goldMedal Andrew Donald Nash (19 out of 29 patents)

silverMedal Con Panousis (16 out of 19 patents)

bronzeMedal Gary Lee Warren (11 out of 11 patents)

4.  Yvonne Vucica (11 out of 11 patents)

5.  Manuel Baca (11 out of 33 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Csl Limited. Retrieved from https://idiyas.com/company/csl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…